Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 274

Similar articles for PubMed (Select 19926893)

1.

Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy.

Mehdi UF, Adams-Huet B, Raskin P, Vega GL, Toto RD.

J Am Soc Nephrol. 2009 Dec;20(12):2641-50. doi: 10.1681/ASN.2009070737. Epub 2009 Nov 19.

2.

Potassium handling with dual renin-angiotensin system inhibition in diabetic nephropathy.

Van Buren PN, Adams-Huet B, Nguyen M, Molina C, Toto RD.

Clin J Am Soc Nephrol. 2014 Feb;9(2):295-301. doi: 10.2215/CJN.07460713. Epub 2014 Jan 9.

3.

Renoprotective effect of the addition of losartan to ongoing treatment with an angiotensin converting enzyme inhibitor in type-2 diabetic patients with nephropathy.

Abe H, Minatoguchi S, Ohashi H, Murata I, Minagawa T, Okuma T, Yokoyama H, Takatsu H, Takaya T, Nagano T, Osumi Y, Kakami M, Tsukamoto T, Tanaka T, Hiei K, Fujiwara H.

Hypertens Res. 2007 Oct;30(10):929-35.

PMID:
18049024
4.

Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function.

van den Meiracker AH, Baggen RG, Pauli S, Lindemans A, Vulto AG, Poldermans D, Boomsma F.

J Hypertens. 2006 Nov;24(11):2285-92.

PMID:
17053552
5.
6.

Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy.

Schjoedt KJ, Rossing K, Juhl TR, Boomsma F, Tarnow L, Rossing P, Parving HH.

Kidney Int. 2006 Aug;70(3):536-42. Epub 2006 Jun 14.

PMID:
16775595
7.

Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy.

Andersen S, Tarnow L, Rossing P, Hansen BV, Parving HH.

Kidney Int. 2000 Feb;57(2):601-6.

8.

Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.

de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE, Brenner BM.

Kidney Int. 2004 Jun;65(6):2309-20.

PMID:
15149345
9.
10.

Predictors of hyperkalemia risk following hypertension control with aldosterone blockade.

Khosla N, Kalaitzidis R, Bakris GL.

Am J Nephrol. 2009;30(5):418-24. doi: 10.1159/000237742. Epub 2009 Sep 9.

PMID:
19738369
12.

Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy.

Jacobsen P, Andersen S, Rossing K, Jensen BR, Parving HH.

Kidney Int. 2003 May;63(5):1874-80.

PMID:
12675866
13.

Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes.

Epstein M, Williams GH, Weinberger M, Lewin A, Krause S, Mukherjee R, Patni R, Beckerman B.

Clin J Am Soc Nephrol. 2006 Sep;1(5):940-51. Epub 2006 Jul 19.

14.

Long-term effects of addition of mineralocorticoid receptor antagonist to angiotensin II receptor blocker in patients with diabetic nephropathy: a randomized clinical trial.

Esteghamati A, Noshad S, Jarrah S, Mousavizadeh M, Khoee SH, Nakhjavani M.

Nephrol Dial Transplant. 2013 Nov;28(11):2823-33. doi: 10.1093/ndt/gft281. Epub 2013 Sep 5.

PMID:
24009294
15.

Aliskiren combined with losartan in type 2 diabetes and nephropathy.

Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK; AVOID Study Investigators.

N Engl J Med. 2008 Jun 5;358(23):2433-46. doi: 10.1056/NEJMoa0708379.

17.
18.

Dual renin-angiotensin system blockade at optimal doses for proteinuria.

Laverman GD, Navis G, Henning RH, de Jong PE, de Zeeuw D.

Kidney Int. 2002 Sep;62(3):1020-5.

19.
20.

Effect of addition of silymarin to renin-angiotensin system inhibitors on proteinuria in type 2 diabetic patients with overt nephropathy: a randomized, double-blind, placebo-controlled trial.

Fallahzadeh MK, Dormanesh B, Sagheb MM, Roozbeh J, Vessal G, Pakfetrat M, Daneshbod Y, Kamali-Sarvestani E, Lankarani KB.

Am J Kidney Dis. 2012 Dec;60(6):896-903. doi: 10.1053/j.ajkd.2012.06.005. Epub 2012 Jul 7.

PMID:
22770926
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk